maximum weight loss tirzepatide surmount trials Presented today at #ECO2026 ⤵️ The SURMOUNT-MAINTAIN trial found that continuing at the tolerated dose maintained bodyweight reduction and health-related benefits in adults with obesity. Explore the research: https://t.co/RjLxWa5qjV For the first time, tirzepatide

Eli Lilly and Company provides access to all individual participant data collected during the trial, after anonymization, except for pharmacokinetic or genetic data

Clinical data shows women typically lose a higher percentage of body weight than men, ranging from 11.5% to 27.6% for women versus 8.8% to 18.9% for men

Routine cost or convenience doesnt qualify

Starvation ketoacidosis is caused by vomiting, diarrhea, and poor caloric intake induced by dual-acting GLP-1 agonists

Neither requires a medical degree to understand

For others, factors like genetics and hormones work against them, placing additional obstacles in their path to success